Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLM NYSE:NKGN NASDAQ:PTIX NYSEAMERICAN:SVT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLMApollomics$6.31+4.2%$6.05$4.47▼$35.98$6.94M0.9223,646 shs13,063 shsNKGNNKGen Biotech$0.13$0.22$0.10▼$0.96$5.96M1.191.61 million shs3,139 shsPTIXAtrinsic$4.24-0.5%$3.28$2.25▼$15.54$2.50M0.341.91 million shs2.21 million shsSVTServotronics$46.94$46.94$9.67▼$47.48$120.17M1.4912,160 shsN/AAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLMApollomics+12.24%+2.28%-6.92%-14.55%-53.82%NKGNNKGen Biotech0.00%-5.36%-36.90%-54.28%-83.67%PTIXAtrinsic+86.84%+38.76%+27.54%-10.50%-56.33%SVTServotronics0.00%0.00%0.00%+23.36%+288.25%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLMApollomics0.0601 of 5 stars0.03.00.00.00.00.00.0NKGNNKGen BiotechN/AN/AN/AN/AN/AN/AN/AN/APTIXAtrinsic0.3676 of 5 stars0.03.00.00.01.11.70.0SVTServotronicsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLMApollomics 0.00N/AN/AN/ANKGNNKGen Biotech 0.00N/AN/AN/APTIXAtrinsic 0.00N/AN/AN/ASVTServotronics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLMApollomics$1.49M4.65N/AN/A$4.48 per share1.41NKGNNKGen BiotechN/AN/AN/AN/A($2.68) per shareN/APTIXAtrinsicN/AN/AN/AN/A$1.96 per shareN/ASVTServotronics$44.92M2.68$0.07 per share658.77$9.20 per share5.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLMApollomics-$53.86MN/A0.00∞N/AN/AN/AN/AN/ANKGNNKGen Biotech-$82.94M-$2.45N/A∞N/AN/AN/A-479.36%N/APTIXAtrinsic-$5.53M-$13.11N/A∞N/AN/A-860.52%-354.19%8/27/2025 (Estimated)SVTServotronics-$1.62M$0.05N/A∞N/A-2.32%-1.23%-0.82%11/6/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLMApollomicsN/AN/AN/AN/AN/ANKGNNKGen BiotechN/AN/AN/AN/AN/APTIXAtrinsicN/AN/AN/AN/AN/ASVTServotronicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLMApollomicsN/A1.391.39NKGNNKGen BiotechN/A0.020.02PTIXAtrinsicN/A0.860.86SVTServotronicsN/A3.461.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLMApollomics19.13%NKGNNKGen Biotech76.17%PTIXAtrinsic7.97%SVTServotronics24.77%Insider OwnershipCompanyInsider OwnershipAPLMApollomicsN/ANKGNNKGen Biotech10.36%PTIXAtrinsic35.00%SVTServotronics33.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLMApollomics451.10 millionN/ANot OptionableNKGNNKGen BiotechN/A44.95 million40.29 millionNot OptionablePTIXAtrinsic2590,000383,000Not OptionableSVTServotronics2702.56 million1.69 millionNot OptionablePTIX, SVT, APLM, and NKGN HeadlinesRecent News About These CompaniesServotronics Completes Merger and Delists SharesJuly 29, 2025 | theglobeandmail.comTransDigm successfully acquires Servotronics in $134M dealJuly 2, 2025 | bizjournals.comServotronics, Inc. (SVT) - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comTransDigm completes $134 million Servotronics dealJuly 2, 2025 | buffalonews.comBTransDigm and Servotronics Announce Successful Completion of Tender Offer and TransDigm's Acquisition of ServotronicsJuly 1, 2025 | prnewswire.comStar Equity Fund’s Successful Servotronics Campaign Leads to Acquisition by TransDigm for $47 per ShareJune 30, 2025 | finance.yahoo.comShareholder withdraws court filings seeking to block Servotronics acquisitionJune 20, 2025 | bizjournals.comServotronics shareholder seeks to block TransDigm acquisitionJune 18, 2025 | bizjournals.comTransDigm Group Incorporated acquiring Servotronics, Inc.June 8, 2025 | magnoliareporter.comMInside the bidding war for ServotronicsJune 7, 2025 | buffalonews.comBServotronics Says TransDigm Sweetens Acquisition Offer To $47/Share, Amends AgreementMay 31, 2025 | nasdaq.comServotronics Deal Rewrite Ignites Shareholder ValueMay 29, 2025 | insidermonkey.comServotronics, Inc.: Servotronics Executes Amendment to the Agreement and Plan of Merger with TransDigmMay 29, 2025 | finanznachrichten.deServotronics stock soars on raised takeover bidMay 29, 2025 | za.investing.comServotronics Executes Amendment to the Agreement and Plan of Merger with TransDigmMay 29, 2025 | finance.yahoo.comServotronics Shares Jump Nearly 25% on Upgraded Buyout Offer from TransDigmMay 29, 2025 | msn.comTransDigm raises offer price for Servotronics to $47/shareMay 29, 2025 | msn.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INZY, TXNM, SVT, PTIX on Behalf of ShareholdersMay 29, 2025 | morningstar.comMAskeladden Capital Presents Plan To Maximize AstroNova’s Shareholder ValueMay 23, 2025 | usatoday.comServotronics investor withdraws proxy campaign after acquisition dealMay 22, 2025 | bizjournals.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePTIX, SVT, APLM, and NKGN Company DescriptionsApollomics NASDAQ:APLM$6.30 +0.26 (+4.21%) Closing price 03:52 PM EasternExtended Trading$6.04 -0.27 (-4.27%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.NKGen Biotech NYSE:NKGN$0.13 0.00 (0.00%) As of 03:35 PM EasternNKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.Atrinsic NASDAQ:PTIX$4.24 -0.02 (-0.47%) Closing price 04:00 PM EasternExtended Trading$4.25 +0.01 (+0.31%) As of 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.Servotronics NYSEAMERICAN:SVT$46.94 0.00 (0.00%) As of 07/1/2025Servotronics, Inc. designs, manufactures, and markets servo-control components and other technology products for aerospace, military, and medical applications in the United States and internationally. It offers high-performance servo valves, including torque motor, hydraulic, and pneumatic valves. The company offers its products to products are sold to commercial aerospace, government, medical, and industrial markets. The company was incorporated in 1959 and is headquartered in Elma, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot 3 Reasons Salesforce Is a Bargain Right Now Broadcom Named in Apple’s $100B U.S. Investment Plan Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access